Respimat® fixed-dose combination in COPD
Boehringer Ingelheim has announced the submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol Respimat®.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Respiratory boehringer ingelheim chronic obstructive pulmonary disease copd Latest News Respimat tiotropium olodaterol Source Type: news
More News: Chronic Obstructive Pulmonary | Drugs & Pharmacology | Marketing | Respiratory Medicine | Spiriva | Tiotropium